Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges
Open accessThe DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index.
Abstract
The mammalian (or mechanistic) target of rapamycin (mTOR) pathway has a key role in the regulation of a variety of biological processes pivotal for cellular life, aging, and death. Impaired activity of mTOR complexes (mTORC1/mTORC2), particularly mTORC1 overactivation, has been implicated in a plethora of age‐related disorders, including human renal diseases. Since the discovery of rapamycin (or sirolimus), more than four decades ago, advances in our understanding of how mTOR participates in renal physiological and pathological mechanisms have grown exponentially, due to both preclinical studies in animal models with genetic modification of some mTOR components as well as due to evidence coming from the clinical experience. The main clinical indication of rapamycin is as immunosuppressive therapy for the prevention of allograft rejection, namely, in renal transplantation. However, considering the central participation of mTOR in the pathogenesis of other renal disorders, the use of rapamycin and its analogs meanwhile developed (rapalogues) everolimus and temsirolimus has been viewed as a promising pharmacological strategy. This article critically reviews the use of mTOR inhibitors in renal diseases. Firstly, we briefly overview the mTOR components and signaling as well as the pharmacological armamentarium targeting the mTOR pathway currently available or in the research and development stages. Thereafter, we revisit the mTOR pathway in renal physiology to conclude with the advances, drawbacks, and challenges regarding the use of mTOR inhibitors, in a translational perspective, in four classes of renal diseases: kidney transplantation, polycystic kidney diseases, renal carcinomas, and diabetic nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, mTOR has opposite effects on autophagy and cell growth and differentiation — mTOR inhibitors might provide renoprotection by activating autophagy, but they might also inhibit cell growth and therefore hinder kidney repair198,199.”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [199]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509 · cited 2×
“, serum- and glucocorticoidinduced protein kinase 1, SGK1; protein kinases C, PKC) has been linked with mTORC2 activation, with important consequences on cell survival, cytoskeleton organization, and cycle progression [14, 20, 21].”
BackgroundmTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485 · cited 2×
“Yet, other driver mutations are also involved in the ccRCC development, including those responsible for the constitutive increase in mTOR activation [123, 124].”
BackgroundProlonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365 · cited 4×
“Yet, there are unique proteins coupled to each complex: mTORC1 is associated with raptor (regulatory-associated protein of mTOR), fundamental for mTORC1 stability and a positive regulator of downstream effectors recruitment and with PRAS40 (proline-rich Akt substrate), a protein which blocks mTORC1 activity; mTORC2 is…”
BackgroundInfluentialA mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053 · cited 3×
“Yet, there are unique proteins coupled to each complex: mTORC1 is associated with raptor (regulatory-associated protein of mTOR), fundamental for mTORC1 stability and a positive regulator of downstream effectors recruitment and with PRAS40 (proline-rich Akt substrate), a protein which blocks mTORC1 activity; mTORC2 is…”
BackgroundReduced Exposure to Calcineurin Inhibitors in Renal Transplantation
Ekberg, H., Tedesco-Silva, H., Demirbas, A., Vítko, Š., Nashan, B., Gürkan, A., Margreiter, R., Hugo, C., Grinyó, J. M., Frei, U., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067411 · Cited by 1,810 · cited 1×
“Tacrolimus, in combination with mycophenolate mofetil or mycophenolate sodium (MMF/MPA), showed a remarkable impact on the incidence of acute rejection, which declined to around 5% and 15%, respectively, with a significant improvement in graft and patient survival to over 90% in the first year after transplantation [6…”
BackgroundVÉZINA, C., KUDELSKI, A., & SEHGAL, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,687 · cited 1×
“: Rapa- (Rapa Nui =Easter Island), -mycin (related to the antifungal properties)), which is a natural antibiotic macrolide firstly isolated from bacterium (Streptomyces hygroscopicus) extracts found on Easter Island soil samples [4].”
BackgroundSellarés, J., de Freitas, D. G., Mengel, M., Reeve, J., Einecke, G., Sis, B., Hidalgo, L. G., Famulski, K., Matas, A., & Halloran, P. F. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03840.x · Cited by 1,590 · cited 1×
“Several factors have been identified to this end, namely, graft quality (older donors, and/or with expanded criteria) and alloantibody-mediated chronic rejection [68].”
Background
Cited by
Autophagy in kidney homeostasis and disease
Tang, C., Livingston, M. J., Liu, Z., & Dong, Z. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0309-2 · Cited by 496
The Role of IL-6 in Cancer Cell Invasiveness and Metastasis—Overview and Therapeutic Opportunities
Rašková, M., Lacina, L., Kejík, Z., Venhauerová, A., Skaličková, M., Kolář, M., Jakubek, M., Rosel, D., Smetana, K., & Brábek, J. (2022) · Cells · doi:10.3390/cells11223698 · Cited by 226
Recent advances and limitations of mTOR inhibitors in the treatment of cancer
Ali, E. S., Mitra, K., Akter, S., Ramproshad, S., Mondal, B., Khan, I. N., Islam, M. T., Sharifi-Rad, J., Calina, D., & Cho, W. C. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02706-8 · Cited by 207
“Adverse reactions such as nephrotoxicity, and increased risk of malignancy or infections require careful monitoring of treatment [108].”
BackgroundmTOR signalling pathway - A root cause for idiopathic autism?
Ganesan, H., Balasubramanian, V., Iyer, M., Venugopal, A., Subramaniam, M. D., Cho, S.-G., & Vellingiri, B. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.7.137 · Cited by 73
“cardiovascular disease (45), renal diseases (46), pulmonary fibrosis (47), and diabetes mellitus (48).”
BackgroundModulation of mTOR Signaling in Cardiovascular Disease to Target Acute and Chronic Inflammation
Kaldirim, M., Lang, A., Pfeiler, S., Fiegenbaum, P., Kelm, M., Bönner, F., & Gerdes, N. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.907348 · Cited by 73
“Meanwhile, mTOR inhibitors have made significant progress in their utilization to modulate the immune response in a variety of disease disorders (6).”
BackgroundContemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015–2021)
Olekšák, P., Nepovimová, E., Chrienová, Ž., Musílek, K., Patočka, J., & Kuča, K. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114498 · Cited by 57
Renal Manifestations of Tuberous Sclerosis Complex
Nair, N., Chakraborty, R., Mahajan, Z., Sharma, A., Sethi, S. K., & Raina, R. (2020) · Journal of Kidney Cancer and VHL · doi:10.15586/jkcvhl.2020.131 · Cited by 57
Mohamed, M. A., Elkhateeb, W. A., & Daba, G. M. (2022) · Bioresources and Bioprocessing · doi:10.1186/s40643-022-00554-y · Cited by 37
“fatigue, neutropenia, and metabolic disorders such as hypercholesterolemia, hypertriglyceridemia, and hyperglycemia, pulmonary toxicity, secondary lymphoma (De Masson et al. 2011; Paplomata et al. 2013; Cheaib et al. 2015; Guimarães et al. 2015; Viana et al. 2018; Arena et al. 2021; Dang et al. 2021).”
BackgroundMechanistic target of rapamycin inhibitors: successes and challenges as cancer therapeutics
Bhaoighill, M. N., & Dunlop, E. A. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.87 · Cited by 36
“Today, rapamycin is used clinically to prevent kidney and cardiac graft rejection in post-transplantation patients([24,25]).”
BackgroundZulkipli, N. N., Zakaria, R., Long, I., Abdullah, S. F., Muhammad, E. F., Wahab, H. A., & Sasongko, T. H. (2020) · Molecules · doi:10.3390/molecules25173991 · Cited by 35
“In addition, rapalogs also have their limitations; for example, in terms of desired molecular effects, the efficacy may be partially limited by their drug action (cytostatic rather than cytotoxic) [13].”
BackgroundHoff, U., Markmann, D., Thurn-Valassina, D., Nieminen-Kelhä, M., Erlangga, Z., Schmitz, J., Bräsen, J. H., Budde, K., Melk, A., & Hegner, B. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266319 · Cited by 34
“Impaired glucose tolerance and induction of diabetes mellitus is a known adverse effect of mTORi such as Rapa [40].”
BackgroundGoligorsky, M. S. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.01.016 · Cited by 33
mTOR Signaling at the Crossroad between Metazoan Regeneration and Human Diseases
Lund-Ricard, Y., Cormier, P., Morales, J., & Boutet, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082718 · Cited by 33
“mTOR modulators for renal recovery are already ongoing clinical trials and were reviewed in 2018 [79].”
BackgroundPodocyte Lysosome Dysfunction in Chronic Glomerular Diseases
Li, G., Kidd, J. M., & Li, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051559 · Cited by 32
“There are clinical evidences showing the serious disadvantage of rapalogues in terms of its desired therapeutic effects, and its cytostatic effect may partially inhibit its efficacy [198].”
BackgroundMiR‐183 delivery attenuates murine lupus nephritis‐related injuries via targeting mTOR
Li, X., Luo, F., Li, J., & Luo, C. (2019) · Scandinavian Journal of Immunology · doi:10.1111/sji.12810 · Cited by 30
Uil, M., Hau, C. M., Ahdi, M., Mills, J. D., Kers, J., Saleem, M. A., Florquin, S., Gerdes, V. E. A., Nieuwland, R., & Roelofs, J. J. T. H. (2019) · Clinical Kidney Journal · doi:10.1093/ckj/sfz145 · Cited by 30
“mTOR was one of the top hits and was chosen to be validated in vitro as mTOR is known to be involved in the pathogenesis of DN [36].”
BackgroundAntioxidant Modulation of mTOR and Sirtuin Pathways in Age-Related Neurodegenerative Diseases
Abdullah, A., Murshid, N. M., & Makpol, S. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02083-1 · Cited by 30
Wu, Q., Lv, Q., Liu, X., Ye, X., Cao, L., Wang, M., Li, J., Yang, Y., Li, L., & Wang, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1083875 · Cited by 29
“Growth factors activate mTORC2; then, mTORC2 phosphorylates substrates, including some AGC-family kinases such as protein kinase B (AKT), serum-and glucocorticoidinduced protein kinase 1(SGK1), and protein kinases C (PKC), subsequently participates in cell survival, regulates ion transport, glucose metabolism, and oth…”
BackgroundHablase, R., Kyrou, I., Randeva, H. S., Karteris, E., & Chatterjee, J. (2024) · Cancers · doi:10.3390/cancers16112160 · Cited by 26
“However, a serious drawback of the first-generation rapalogues was the compensatory activation of upstream pathways with no or partial block of mTORC2, eventually deregu-lating the entire mTOR network and compromising the inhibitory activity [179].”
BackgroundLysosomal EGFR acts as a Rheb-GEF independent of its kinase activity to activate mTORC1
He, X., Wang, Q.-X., Wei, D., Lin, Y., Zhang, X., Wu, Y., Qian, X., Lin, Z., Xiao, B.-B., Wu, Q., et al. (2025) · Cell Research · doi:10.1038/s41422-025-01110-x · Cited by 22
“71,72 A known disadvantage of mTOR inhibitors is their tendency to activate AKT pathways via a feedback mechanism, which may favor tumor survival and undermine therapeutic outcomes.”
Khaddour, K., Murakami, N., Ruiz, E. S., & Silk, A. W. (2024) · Cancers · doi:10.3390/cancers16173083 · Cited by 20
“…of mTOR inhibitors must be balanced with its effectiveness to prevent allograft rejection, the increased risk of cardiovascular events, and the impairment of wound healing which could increase complications if surgical excision or radiation therapy (RT) are planned for the management of CSCC [61].”
BackgroundInterrelation of Natural Polyphenol and Fibrosis in Diabetic Nephropathy
Ma, Y., Wang, J., Fan, J., Jia, H., & Li, J. (2024) · Molecules · doi:10.3390/molecules30010020 · Cited by 20
“For instance, studies have shown that the mTORC1 inhibitor rapamycin significantly alleviates fibrosis by activating autophagy [43].”
Metabolic Interventions in Tumor Immunity: Focus on Dual Pathway Inhibitors
Chen, M., Lan, H., Yao, S., Jin, K., & Chen, Y. (2023) · Cancers · doi:10.3390/cancers15072043 · Cited by 20
“However, despite the benefits of this therapeutic method, using these inhibitors could have adverse reactions such as nephrotoxicity and increased risk of infections requiring conscientious monitoring of the treatment [18].”
BackgroundMetabolic regulation of Th17 and Treg cell balance by the mTOR signaling
Wang, Z., Xu, Z., Zong, M., & Fan, L. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100369 · Cited by 20
“The development of second-generation mTOR inhibitors with improved potency and reduced toxicity may optimize their use in clinical settings [79,81,82].”
Chowdhury, O., Bammidi, S., Gautam, P., Babu, V. S., Liu, H., Shang, P., Xin, Y., Mahally, E., Nemani, M., Koontz, V., et al. (2025) · Aging Cell · doi:10.1111/acel.70018 · Cited by 19
“Although rapamycin has shown antiangiogenic potential in AMD, clinical results have been inconsistent due to factors like limited bioavailability and off-target effects (Viana et al. 2018; Wu et al. 2022).”
Role of mTOR complex in IGF-1 induced neural differentiation of DPSCs
Huang, D., Shen, S., Cai, M., Lin, J., Lü, J., Xu, K., Zhang, J., Feng, G., Hu, Y., Zheng, K., et al. (2019) · Journal of Molecular Histology · doi:10.1007/s10735-019-09825-z · Cited by 19
Cheng, X., Chen, Q., & Sun, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.970596 · Cited by 17
“The mTOR protein kinase, a major negative regulator of autophagy (Viana et al., 2018), is involved in several signaling pathways that control cell growth, most of which are downstream of growth factor receptors with tyrosine kinase activity.”
BackgroundSiniprasad, P., Nair, B., Balasubramaniam, V., Sadanandan, P., Namboori, P. K., & Nath, L. R. (2020) · Letters in Drug Design & Discovery · doi:10.2174/1570180817999200623115703 · Cited by 15
The critical role of dysregulated autophagy in the progression of diabetic kidney disease
Zhang, Z., Sun, Y., Xue, J., Jin, D., Li, X., Zhao, D., Lian, F., Qi, W., & Tong, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.977410 · Cited by 15
Du, Y. Z., & Cai, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114905 · Cited by 15
Hyperglycemia and Hyperlipidemia with Kidney or Liver Transplantation: A Review
D’Elia, J. A., & Weinrauch, L. A. (2023) · Biology · doi:10.3390/biology12091185 · Cited by 15
“The mTOR complex located in the renal tubular epithelial cell is involved in the generation of polycystic kidney disease [8,9].”
BackgroundMTOR promotes basal cell carcinoma growth through atypical PKC
Chow, R. Y., Levee, T. M., Kaur, G., Cedeno, D. P., Doan, L. T., & Atwood, S. X. (2020) · Experimental Dermatology · doi:10.1111/exd.14255 · Cited by 10
“We used everolimus despite a slight increase in Gli1 expression in ASZ001 mouse BCC cells because it is FDA approved and has been shown to be more effective in treating certain cancers and other diseases than rapamycin[29, 30, 31, 32].”
MethodDebenedette, M. A., Gamble, A. H., Norris, M. S., Horvatinovich, J. M., & Nicolette, C. A. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2220629 · Cited by 9
“84,85 Our data may reveal a unique mechanism of action for everolimus in combination therapy based on the ability to modulate B cell secretion of TGF-β into the plasma of mRCC subjects.”
BackgroundmTORC1 Deficiency Modifies Volume Homeostatic Responses to Dietary Sodium in a Sex-Specific Manner
Brooks, D. L. P., Garza, A., Guzelce, E. C., Gholami, K., Treesaranuwattana, T., Maris, S. A., Ranjit, S., Tay, C. S., Lee, J. M., Romero, J. R., et al. (2020) · Endocrinology · doi:10.1210/endocr/bqaa041 · Cited by 6
Güden, D. S., Temiz-Reşitoğlu, M., Şenol, Ş. P., Kibar, D., Yilmaz, S. N., Tunçtan, B., Malik, K. U., & Şahan-Fırat, S. (2021) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2020-0487 · Cited by 6
Lee, C., Wan, Y., Smith, A. D., Xie, R., & Motzer, R. J. (2021) · European Urology Open Science · doi:10.1016/j.euros.2021.06.008 · Cited by 5
Senomorphic, senolytic, and rejuvenation therapies
Zhu, X. Y., & Lerman, L. O. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823318-4.00025-1 · Cited by 4
Gerosuppressive and Senolytic Nutrients
Nehlin, J. O. (2021) · Healthy ageing and longevity · doi:10.1007/978-3-030-83017-5_22 · Cited by 3
Singh, P., Mittal, A., & Chitkara, D. (2025) · Microchemical Journal · doi:10.1016/j.microc.2025.114567 · Cited by 1
The role of amino acid signaling in pathogenesis of chronic kidney disease
Yan, S., Zhang, X., Bu, R., Li, G., Wang, Y., Cheng, M., Chen, Q., Wu, Y. C., Zhang, Y., Wang, D., et al. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05447-0 · Cited by 1
Gilewski, W., Banach, J., Rogowicz, D., Wołowiec, Ł., Sielski, S., & Grześk, G. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001009 · Cited by 1
Stress-induced senescence as a forme fruste of chronic kidney disease—A case for failed regeneration
Goligorsky, M. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823318-4.00001-9 · Cited by 1
Targeting Autophagic Pathway in Oral Cancer Therapy Through Phytoconstituents: A Short Review
Satpathy, S., Bhuyan, S. K., & Bhuyan, R. (2024) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2890 · Cited by 1
Targeting mTOR: up-to-date mTOR inhibitors
Kilic, B., Temiz-Reşitoğlu, M., & Fırat, S. Ş. (2019) · Bioorganic & Medicinal Chemistry Reports · doi:10.25135/bmcr.16.19.09.1417
The role of platelets in diabetic nephropathy and renal fibrosis
Uil, M. (2020) · Pure Amsterdam UMC
Therapeutic cell reconditioning
Goligorsky, M. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823318-4.00005-6
Lee, C. H., Wan, Y., Smith, A., Xie, R., & Motzer, R. J. (2021) · Cancer Urology · doi:10.17650/1726-9776-2021-17-4-54-64
Devapatla, P., Teng, Y. G., Settipalli, P. C., Yeruva, P. K. R., Hsieh‐Li, H. M., & Shaik, A. (2025) · The FASEB Journal · doi:10.1096/fj.202503323r
BindingDB (2023) · UC San Diego · doi:10.7270/q2zg6xb2
Metadata
- Authors
- Viana, S. D., Reis, F., & Alves, R.
- Affiliations
- Universidade Politécnica de Coimbra (PT)
- Centro de Inovação em Biomedicina e Biotecnologia (PT)
- Unidade Local de Saúde de Coimbra (PT)
- Corresponding author
- Reis, Flávio
- Alves, Rui
- Venue
- Oxidative Medicine and Cellular Longevity
- Publisher
- Wiley
- Published
- 2018-01
- Volume
- 2018
- Issue
- 1
- Pages
- 3693625-3693625
- ISSN
- 1942-0994 (ISSN-L)
- 1942-0900
- PMC
- PMC6231362
- OpenAlex
- W2899387091
- Cited by
- 48
- References
- 154
- Citations by year
- 2025: 6 · 2024: 4 · 2023: 6 · 2022: 8 · 2021: 8 · 2020: 10 · 2019: 6
- FWCI
- 0.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Oxidative Medicine and Cellular Longevity (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by)
- Funders
- Fundação para a Ciência e a Tecnologia
- European Regional Development Fund
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- mTOR inhibitors, mTOR signaling, mTORC1, mTORC2, rapamycin, everolimus, temsirolimus, kidney disease, kidney transplantation, polycystic kidney disease, renal carcinoma, diabetic nephropathy, immunosuppression, age-related diseases
- MeSH terms
- Animals, Humans, Kidney Diseases, Protein Kinase Inhibitors, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.